CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)

Summary

This study was a single-arm, multi-center, phase II study, which is aimed to evaluate the efficacy and safety of CM082 combined with JS001 as the second-line treatment of advanced small cell lung cancer. Eligible patients will receive CM082 tablets 150mg once daily orally in combination with JS001 (240mg, intravenously) every 21 days. Treatment continues until disease progresses , intolerable toxicity, or withdraw.

Timeline

Start

2019-09-18

Primary completion

2021-06-30

Completion

2021-12-31

Drugs

Indications